ERBB2 and breast cancer: The results demonstrated that the combination of everolimus and exemestane prolonged the median PFS in postmenopausal patients with late-stage HR-positive/HER2-negative breast cancer who relapsed or progressed after AI therapy; the HR = 0.45 (84).